Edit
Rempex Pharmaceuticals
http://www.rempexpharma.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 29.06.2012
Active
50岁熟妇高潮惨叫,吸奶头吸到高潮免费观看,伊人av无码av中文av狼人,国产精品v日韩精品v欧美精品,成熟少妇的A片免费看,免费A级毛片无码A∨免费,yw尤物AV无码国产在线看
Total raised: $67.5M
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.11.2011 | Series B | $67.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 29.06.2012 | Device would let clinicians screen for bacteria, pick best antibiotic in an hour | “A lot of the bacterial tests out there use PCR, which is a technique of attaching DNA on to a probe,” Nickel said. “Ours is strictly based on the electronic sensor and the sensor’s ability to monitor the bacterial activity.” Nickel said it... |
| 09.11.2011 | Rempex Pharmaceuticals Completes Initial Closing of $67.5M Series B Financing | Rempex Pharmaceuticals, Inc., a San Diego, CA-based biopharmaceutical company that focuses on developing internally discovered new treatments for resistant gram-negative infections has completed the initial closing of a Series B financing. ... |
| 09.11.2011 | Rempex Inks Series B Financing of Up to $67.5M | Rempex Pharmaceuticals announced that it has completed the initial closing of a Series B financing. New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street ... |
| 09.11.2011 | Rempex Pharmaceuticals Snags $67.5M | San Diego-based Rempex Pharmaceuticals, a biopharmaceuticals firm addressing antibiotic resistance, announced this morning that it has raised $67.5M in an initial close of a Series B financing round. The round came from Frazier Healthcare V... |
| - | Device would let clinicians screen for bacteria, pick best antibiotic in an hour | Lately we’ve seen a lot of rapid diagnostics for bacterial infections like MRSA, tuberculosis and streptococcus. This early-stage startup is doing it a little differently: it’s focusing less on identifying the bacteria and more on rapidly d... |